Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models

Oct 26, 2005Neurobiology of disease

Abnormal levels of Dyrk1A protein in Alzheimer’s, Down syndrome, Pick disease, and related experimental models

AI simplified

Alzheimers & Treatments on OpenScience ↗PubMed ↗DOI ↗

Abstract

Increased Dyrk1A immunoreactivity is found in the cytoplasm and nuclei of scattered neurons in the neocortex, entorhinal cortex, and hippocampus in Alzheimer's disease, Down syndrome with associated Alzheimer's disease, and Pick disease.

Dyrk1A maps to human chromosome 21 within the Down syndrome critical region.
Phosphorylation of tau at Thr212 by Dyrk1 primes it for further modification by glycogen synthase kinase 3.
Dyrk1A is present in sarkosyl-insoluble fractions enriched in phosphorylated tau in Alzheimer's disease brains.
No clear relationship is observed between tau phosphorylation at Thr212 and Dyrk1A expression in diseased brains.
Transgenic mice with hyper-phosphorylated tau show increased Dyrk1A expression in neurons, but over-expression of Dyrk1A does not lead to increased phosphorylation of tau at Thr212.

AI simplified

DYRK1A, dual-specificity tyrosine-regulated kinase 1A, maps to human chromosome 21 within the Down syndrome (DS) critical region. Dyrk1 phosphorylates the human microtubule-associated protein tau at Thr212 in vitro, a residue that is phosphorylated in fetal tau and hyper-phosphorylated in Alzheimer disease (AD) and tauopathies, including Pick disease (PiD). Furthermore, phosphorylation of Thr212 primes tau for phosphorylation by glycogen synthase kinase 3 (GSK-3). The present study examines Dyrk1A in the cerebral cortex of sporadic AD, adult DS with associated AD, and PiD. Increased Dyrk1A immunoreactivity has been found in the cytoplasm and nuclei of scattered neurons of the neocortex, entorhinal cortex, and hippocampus in AD, DS, and PiD. Dyrk1A is found in sarkosyl-insoluble fractions which are enriched in phosphorylated tau in AD brains, thus suggesting a possible association of Dyrk1A with neurofibrillary tangle pathology. Yet, no clear relationship has been observed between tau phosphorylation at Thr212, and GSK-3 and Dyrk1A expression in diseased brains. Transgenic mice bearing a triple tau mutation (G272V, P301L, and R406W) and expressing hyper-phosphoyrylated tau in neurons of the entorhinal cortex, hippocampus, and cerebral neocortex show increased expression of Dyrk1A in individual neurons in the same regions. However, transgenic mice over-expressing Dyrk1A do not show increased phosphorylation of tau at Thr212, thus suggesting that Dyrk1A over-expression does not trigger per se hyper-phosphorylation of tau at Thr212 in vivo. The present observations indicate modifications in the expression of constitutive Dyrk1A in the cytoplasm and nuclei of neurons in various neurodegenerative diseases associated with tau phosphorylation.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the alzheimers & treatments brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the alzheimers & treatments brief